The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2019 | Is MRD monitoring prior to allograft standard in AML?
Michael Heuser
• 25 Oct 2019
Michael Heuser, MD, Hannover Medical School, Hannover, Germany, talks on standard practice and measurable residual disease (MRD) monitoring prior to allograft in acute myeloid leukemia (AML). This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
